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j ourna l homepage: www.eb iomed ic ine.comEditorialDisease, iPSCs and a Quest for the Perfect ModelTen years ago Shinya Yamanaka and colleagues from Kyoto Univer-
sity (Japan) described the creation of induced pluripotent stem
cells (iPSCs), ﬁrst from mice, then humans a year later. The ability to
‘reprogram’ mature cells into iPSCs by introducing genes that encode
speciﬁc transcription factors, enables them to divide indeﬁnitely and
give rise to any cell type in the body. This pioneering feat won
Yamanaka the Nobel Prize in 2012 and revolutionized stem cell biology.
The biomedical promise was great: it was hoped that patient-derived
iPSCs could be used to replenish damaged or diseased tissue. However,
the inability to predict iPSC behavior when injected in vivo has hindered
their direct regenerative utility. This was exempliﬁed when the ﬁrst
clinical trial using cells derived from human iPSCs was recently
suspended owing to genomic abnormalities, as reported by Nature
Biotechnology on September 8, 2015.While iPSC researchers are spend-
ing considerable efforts circumventing this challenge, their use as an
in vitro platform to model disease has ﬂourished.
There is a constant need to develop highly relevant preclinical dis-
ease models. The better the model, the greater the chance of ﬁnding
clinically-useful answers. The advent of patient-derived iPSCs offers
several advantages over traditional cell culture. First, unlike regular so-
matic cells that divide a limited number of times, iPSCs can self-renew,
thereby offering a limitless supply of human cells to develop in vitro
models. Second, iPSCs derived from patients with a disease can recapit-
ulate the genetic and epigenetic features of that disease more faithfully
than existing established cell lines. iPSCs provide an opportunity to
dissect theunderlyingpathophysiology and interrogate themwith ther-
apeutic agents to assess and tailor their response.
Kevin Eggan and Clifford Woolfe, from the Harvard Stem Cell Insti-
tute (USA), harnessed this potential by deriving motor neurons from
iPSCs made from patients with the fatal neurodegenerative disorder,
amyotrophic lateral sclerosis (ALS). They found that ALS patient-
derived motor neurons that harbor mutations in superoxide dismutase
1 (SOD1) display a hyperexcitability phenotype due to a deﬁcit in potas-
sium channels at the cell membrane. Furthermore, they demonstrated
that retigabine, an anti-seizure drug that opens potassium channels,
can normalize this phenotype and increase their survival. This ﬁnding
precipitated an interventional Phase 2 clinical trial and ALS patients
are currently being recruited to receive retigabine (NCT02450552).
This dish-to-patient study exempliﬁes the translational potential of
iPSC technology. It also challenges the traditional practice of testing
drugs in animal models, expediting the process and bypassing a costly,
ethically problematic and often scientiﬁcally-ﬂawed system.
It was also discovered that iPSCs, when grown in speciﬁc culture
conditions, had an intrinsic capacity to form self-organized clusters of
cells. These 3D structures were termed ‘organoids’, after their ability
to mimic certain aspects of an organ's in vivo physiology. Organoidshttp://dx.doi.org/10.1016/j.ebiom.2016.02.005
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ble and tractable model system. Many comprise multiple tissue-types,
recreating the reciprocal cellular interactions found in the body. Kidney,
hepatic, intestinal, pancreatic, gastric, lung, fallopian tube, testicular and
salivary gland organoids have already been described and used to
address biological questions that were otherwise impossible using
standard 2D culture. In 2013, Madeline Lancaster, now at the University
of Cambridge (UK), developed a protocol for culturing cerebral
organoids — had the last and grandest biological frontier been con-
quered? Analyzing their gene expression programs revealed remark-
able similarity to the fetal neocortex. However, tissue and batch
heterogeneity remain a challenge, driving the quest for new protocols
that can enrich speciﬁc neuronal cell types and direct organoids towards
a desired neural phenotype.
Nevertheless, organoids derived from patient-iPSCs have already
been deployed for clinical gains. For example, human intestinal
organoids have been used to study cancer, cystic ﬁbrosis (CF) and in-
ﬂammatory bowel disease in the laboratory of Hans Clevers at Hubrecht
Institute (TheNetherlands). Interestingly, organoids derived from rectal
biopsies of CF patients fail to ‘swell up’ when cultured in forskolin,
unlike healthy counterparts. This functional organoid assay enables
the identiﬁcation of patient responders to a given drug, saving time
and money on administering ineffective drugs and providing a person-
alized approach to tackle CF.
If iPSCs can model disease at a cellular level, and organoids can
model disease at a tissue level, is there a way of modeling disease at
an organ or even systems level? Several institutes have embarked on
organs-on-a-chip technology, a platform that combines cutting-edge
bioengineering devices with multiple cell types to create a microchip
with organ functionality. For example, TheWyss Institute for Biological-
ly Inspired Engineering at Harvard University (USA; http://wyss.
harvard.edu/), have created a lung-on-a-chip that comprises a porous
membrane separating lung and capillary cells, and ﬂanking channels
that recreate mechanical stress, air ﬂow and the blood stream. This
chip has been used to mimic pulmonary edema, the immune response
to bacterial insult, and personalized by incorporating patient cells to un-
derstand their function and response to therapy. Their ultimate goal is
to recreate 10 different organs-on-a-chip, then test if they can function
together when placed in parallel to replicate a system, the so-called
body-on-a-chip. The deadline for this ambitious challenge is early
2017 and the world will be waiting to see if this goal can be achieved.
The ability to meld scientiﬁc disciplines to develop state-of-the-art
disease models has entered an extremely exciting phase. It is important
that biorepositories are effectively characterized, cataloged and coordi-
nated to maximize the useful information that can be gleaned. John
Gurdon, co-recipient of the Nobel prize with Yamanaka once said “It is-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2 Editorialparticularly pleasing to see how purely basic research, originally aimed
at testing the genetic identity of different cell types in the body, has
turned out to have clear human health prospects.” The full extent that
human health will beneﬁt remains to be seen, but this truly is transla-
tional medicine in action.EBioMedicine
